BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37602660)

  • 1. Outcomes and prognostic factors of patients with Extranodal NK T cell lymphoma (ENKTL).
    Rajendra A; Sengar M; Bonda VNA; Jain H; Nayak L; Thorat J; Shet T; Epari S; Laskar S; Aggarwal A; Rangarajan V; Gujral S; Bagal B; Kakoti S; Salvi O
    Leuk Lymphoma; 2023 Dec; 64(12):1914-1926. PubMed ID: 37602660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A five
    Vittayawacharin P; Khuhapinant A
    Hematology; 2021 Dec; 26(1):75-82. PubMed ID: 33427594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
    Miyazaki K; Suzuki R; Oguchi M; Taguchi S; Amaki J; Maeda T; Kubota N; Maruyama D; Terui Y; Sekiguchi N; Takizawa J; Tsukamoto H; Murayama T; Ando T; Matsuoka H; Hasegawa M; Wada H; Sakai R; Kameoka Y; Tsukamoto N; Choi I; Masaki Y; Shimada K; Fukuhara N; Utsumi T; Uoshima N; Kagami Y; Asano N; Ejima Y; Katayama N; Yamaguchi M
    Hematol Oncol; 2022 Oct; 40(4):667-677. PubMed ID: 35142384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy.
    Zhang YP; Zhang R; Zhu HY; Wang L; Wu YJ; Liang JH; Shi WY; Liu H; Xu W; Li JY
    Cancer Res Treat; 2019 Jan; 51(1):368-377. PubMed ID: 29764116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of prognostic factors of extranodal NK/T-cell lymphoma treated with pegaspargase/L-asparaginase: a multicenter retrospective study].
    Shen ZY; Chen XC; Shan HR; Jia T; Gu WY; Wang F; Teng QL; Wang L; Wang CL; Shi YY; Zhang H; Miao YQ; Zhu TG; Ji CY; Ye JJ; Zhang MZ; Zhang XD; Wang L; Xu KL; Sang W
    Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):642-648. PubMed ID: 37803837
    [No Abstract]   [Full Text] [Related]  

  • 6. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.
    Lim SH; Hong JY; Lim ST; Hong H; Arnoud J; Zhao W; Yoon DH; Tang T; Cho J; Park S; Ko YH; Kim SJ; Suh C; Lin T; Kim WS
    Ann Oncol; 2017 Sep; 28(9):2199-2205. PubMed ID: 28911074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of chemotherapy with or without asparaginase for extranodal nasal NK/T-cell lymphoma in children and adolescents.
    Zhen Z; Huang H; Lin T; Li Z; Zhen X; Xia Z; Zhu J; Lu S; Sun F; Wang J; Huang J; Sun X
    Pediatr Blood Cancer; 2021 May; 68(5):e28901. PubMed ID: 33484107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line LVDP (L-asparaginase, etoposide, dexamethasone, and cisplatin) regimen combined with radiotherapy is effective for early-stage extranodal natural killer/T-cell lymphoma, nasal type.
    Wu W; Chen X; Li N; Luo Q; Zou L
    Ann Hematol; 2022 Jul; 101(7):1557-1565. PubMed ID: 35585247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A proposal for a prognostic index for non-nasal type natural killer/T cell lymphoma after asparaginase-based treatment.
    Chen Z; Fang X; Huang H; Wang Z; Hong H; Chen M; Ren Q; Yao Y; Zhang L; Tian Y; Lin S; Lin T
    Ann Hematol; 2020 Dec; 99(12):2811-2819. PubMed ID: 32975588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the clinical efficacies of two L-asparaginase-based chemotherapy regimens for newly diagnosed nasal-type extranodal NK/T-cell lymphoma.
    Wu W; Ren K; Chen X; Li N; Luo Q; Hai T; Zhou H; Zou L
    Cancer Med; 2023 Apr; 12(8):9458-9470. PubMed ID: 37000008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
    Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
    EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (NK/T)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study.
    Xu Y; Wang J; Zhang W; Liu J; Cao X; He A; Chen Y; Gu L; Lei B; Zhang P; Ma X
    Med Sci Monit; 2016 Nov; 22():4297-4311. PubMed ID: 27843135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central nervous system involvement at initial diagnosis of extranodal NK/T-cell lymphoma: a retrospective study of a consecutive 12-year case series.
    Wu W; Ren K; Li N; Luo Q; Zhou H; Hai T; Zou L
    Ann Hematol; 2023 Apr; 102(4):829-839. PubMed ID: 36729147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.
    Wei W; Wu P; Li L; Zhang ZH
    Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.
    Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ
    Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Sandwich" protocol based on modified SMILE regimen for children with newly extranodal NK/T cell lymphoma, nasal type: a single-arm, single-center clinical study.
    Shen CQ; He GQ; Wan Z; Lin C; Yang X; Lu XX; Zhu YP; Gao J; Guo X
    Ann Hematol; 2023 Nov; 102(11):3143-3152. PubMed ID: 37486391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical study of l-asparaginase in the treatment of extranodal NK/T-cell lymphoma, nasal type.
    Yong W
    Hematol Oncol; 2016 Jun; 34(2):61-8. PubMed ID: 25899032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
    Wei L; Yang L; Cong J; Ye J; Li X; Yao N; Yang J; Ding J; Wang J
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):863-869. PubMed ID: 33025280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report.
    Xu J; Xu X; Chen J; Wang J; Jiang C; Lv C; Chen B
    Medicine (Baltimore); 2021 Mar; 100(10):e24824. PubMed ID: 33725836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Study of L-Asparaginase-Based LOP Regimen Over CHOP Regimen Before Radiotherapy for Stage IIE Extranodal Nasal Type NK/T Cell Lymphoma: A Study of 2 Centers.
    Huang L; Yuan B; Wu H; Chu H; Liu Y; Wu S; Li H; Lu H; Chen H
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):152-158. PubMed ID: 28215935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.